Joshua Hare, MD
Cardiovascular Disease · Miami, FLNPI 1548209109
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Daiichi Sankyo Inc. at 48.9% of the total. Reporting peaked in 2022 at $16,382 and has fallen 98.9% since, to $188 in 2025. Among cardiovascular disease clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 35 payments — averaging $650.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$11K
- Merck$10K
- Bayer$1K
- Boston Scientific$361
- Edwards Lifesciences$163
- Abbott$113
- plus $59 from 2 others
Across 31 payments — averaging $399.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim Pharma GmbH & Co.kg$7K
- Boehringer Ingelheim International GmbH$6K
What the payments were for
- Consulting fees$11,13849%
- Speaking & faculty fees$8,54038%
- Travel & lodging$1,9599%
- Food & beverage$1,1345%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 1 | $11,138 |
| Merck | 8 | $9,664 |
| Bayer | 9 | $1,272 |
| Boston Scientific | 12 | $361 |
| Edwards Lifesciences | 1 | $163 |
| Abbott | 1 | $113 |
| Medtronic | 2 | $36 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERQUVO$9,591
- MITRIS RESILIA Mitral Valve$163
- Trifecta GT Tissue Heart Valve$113
- Sentinel$112
How this compares
$22,770 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 58 | $67,419 |
| JardianceEmpagliflozin | 22 | $22,742 |
| EliquisApixaban | 11 | $11,517 |
| Repatha SureclickEvolocumab | 11 | $6,127 |
| Rosuvastatin Calcium | 17 | $355 |
| Metoprolol Succinate | 22 | $289 |
| Atorvastatin Calcium | 37 | $262 |
| Losartan Potassium | 14 | $221 |
| Carvedilol | 21 | $195 |
| ClopidogrelClopidogrel Bisulfate | 14 | $177 |
| Levothyroxine Sodium | 13 | $163 |
| Spironolactone | 13 | $61 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Miami
- Theodore FeldmanMiami$637K
- Elliott EliasMiami$497K
- Ian del Conde PozziMiami$243K
- Jonathan FialkowMiami$153K
- Bernard AshbyMiami$115K
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.